Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.

Cationic hyaluronic acid (HA)-modified DOTAP/DOPE liposomes were designed for the targeted delivery of anti-telomerase siRNA to CD44 receptor-expressing lung cancer cells. DOTAP/DOPE liposomes modified with 1%-20% (w/w) HA-DOPE conjugate were obtained by the ethanol injection method. Their size was below 170 nm and they exhibited zeta potentials higher than +50 mV. Lipoplexes prepared at different +/-ratios with siRNA were in the range of 200 nm and below and their zeta potentials were strongly dependent on the degree of modification and the +/-charge ratio. The presence of HA did not compromise binding, protection of siRNA from degradation, and complex stabilities in serum but rather resulted in an improvement of these properties. Liposome cytotoxicity, investigated by the MTT assay and LDH release after treatment of CD44(+) A549 cells and CD44(-) Calu-3, was demonstrated only at high concentrations. However, the addition of siRNA to HA-modified liposomes prevented cytotoxic effects compared to all other formulations. As shown by flow cytometry, transfection of siRNA into A549 cells was markedly improved with HA-modified liposomes, but not into Calu-3 cells. Using a qPCR-TRAP assay to test telomerase activity, no difference was demonstrated in the efficiency between HA-modified and nonmodified preparations. Moreover, some reduction in telomerase activity was observed with liposomes alone, lipoplexes prepared with nonsense siRNA and lipofectamine, indicative for some direct inhibitory effect of the lipids and siRNA on the expression of this enzyme. HA-modified DOTAP/DOPE liposomes represent a suitable carrier system for siRNA since properties like binding or protection of siRNA are not altered. They display an improved stability in cell culture medium and a reduced cytotoxicity. Furthermore, these novel lipoplexes could successfully be targeted to CD44-expressing A549 cells opening interesting perspectives for the treatment of lung cancer.

[1]  T. Park,et al.  Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition. , 2007, Bioconjugate chemistry.

[2]  J. Shay,et al.  Telomerase therapeutics for cancer: challenges and new directions , 2006, Nature Reviews Drug Discovery.

[3]  M. Björkholm,et al.  Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. , 2001, Clinical chemistry.

[4]  Nam W. Kim,et al.  Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP) , 1997, Nucleic Acids Res..

[5]  Michael R. Green,et al.  Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). , 2004, RNA.

[6]  D. Peer,et al.  Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models , 2004, International journal of cancer.

[7]  S. Jothy.  CD44 and its partners in metastasis , 2004, Clinical & Experimental Metastasis.

[8]  T. Park,et al.  Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. , 2008, Biopolymers.

[9]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[10]  R. Margalit,et al.  Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. , 1998, Archives of biochemistry and biophysics.

[11]  Lilly Y. W. Bourguignon,et al.  Signaling Properties of Hyaluronan Receptors* , 2002, The Journal of Biological Chemistry.

[12]  Yu-Kyoung Oh,et al.  Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Leaf Huang,et al.  Surface‐Modified LPD Nanoparticles for Tumor Targeting , 2006, Annals of the New York Academy of Sciences.

[14]  F. Szoka,et al.  Interactions of hyaluronan-targeted liposomes with cultured cells: modeling of binding and endocytosis. , 2004, Methods in enzymology.

[15]  J. Shay,et al.  Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol , 2006, Nature Protocols.

[16]  M. de la Fuente,et al.  Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells , 2008, The journal of gene medicine.

[17]  P. Herrlich,et al.  CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.

[18]  John W. Park,et al.  Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides* , 1998, The Journal of Biological Chemistry.

[19]  G. Prestwich,et al.  Targeted Delivery of Doxorubicin by HPMA Copolymer-Hyaluronan Bioconjugates , 2002, Pharmaceutical Research.

[20]  Guihua Sun,et al.  A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  D. Peer,et al.  Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. , 2004, Neoplasia.

[22]  F. He,et al.  Cationic lipids enhance siRNA-mediated interferon response in mice. , 2005, Biochemical and biophysical research communications.

[23]  E. Korn,et al.  Single bilayer liposomes prepared without sonication. , 1973, Biochimica et biophysica acta.

[24]  C. Culmsee,et al.  siRNA delivery by a transferrin‐associated lipid‐based vector: a non‐viral strategy to mediate gene silencing , 2007, The journal of gene medicine.

[25]  Tyra G. Wolfsberg,et al.  Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Pitsillides,et al.  Hyaluronan synthesis and degradation in cartilage and bone , 2008, Cellular and Molecular Life Sciences.

[27]  G. Devi,et al.  siRNA-based approaches in cancer therapy , 2006, Cancer Gene Therapy.

[28]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[29]  F. Szoka,et al.  Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. , 2001, Cancer research.

[30]  G. Prestwich,et al.  A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. , 2000, Biomacromolecules.

[31]  J. Kremer,et al.  Vesicles of variable diameter prepared by a modified injection method. , 1977, Biochemistry.

[32]  N Toub,et al.  Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.